Biologics in children’s autoimmune disorders: efficacy and safety
- 17 June 2010
- journal article
- review article
- Published by Springer Science and Business Media LLC in European Journal of Pediatrics
- Vol. 170 (2), 157-167
- https://doi.org/10.1007/s00431-010-1238-z
Abstract
No abstract availableKeywords
This publication has 95 references indexed in Scilit:
- Use of Canakinumab in the Cryopyrin-Associated Periodic SyndromeThe New England Journal of Medicine, 2009
- Adalimumab with or without Methotrexate in Juvenile Rheumatoid ArthritisThe New England Journal of Medicine, 2008
- Pharmacogenetics of etanercept in rheumatoid arthritisPharmacogenomics, 2008
- Efficacy and safety of rilonacept (interleukin‐1 trap) in patients with cryopyrin‐associated periodic syndromes: Results from two sequential placebo‐controlled studiesArthritis & Rheumatism, 2008
- Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trialThe Lancet, 2008
- Biologic treatments for systemic rheumatic diseasesOral Diseases, 2008
- When should we use TNF antagonists in children with rheumatic disease?Joint Bone Spine, 2007
- Rates of serious infection, including site‐specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti–tumor necrosis factor therapy: Results from the British Society for Rheumatology Biologics RegisterArthritis & Rheumatism, 2006
- Infliximab Therapy in 30 Patients With Refractory Pediatric Crohn Disease With and Without Fistulas in The NetherlandsJournal of Pediatric Gastroenterology and Nutrition, 2004
- Use of biologics in the treatment of childhood rheumatic diseases.Current Rheumatology Reports, 2000